Precision AAV Targeting in Muscle Tissue: Key Strategies for Successful Gene Therapy in Muscular Disorders
Muscle gene therapy is rapidly moving from promise to practice. On May 14, 2026, REGENXBIO reported positive pivotal interim results from its RGX-202 program that drew significant attention from the biotech and pharmaceutical sectors to the potential of AAV-based muscle gene therapy [1]. For devastating conditions like Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophy (LGMD), the ability to deliver therapeutic genes efficiently and specifically to muscle tissue can mean the difference between incremental progress and transformative outcomes.
Adeno-associated virus (AAV) vectors remain the leading platform for this work, but success depends on precise targeting. Off-target expression, limited transduction of certain muscle groups, and immune considerations continue to challenge researchers.
In this article, we break down the latest AAV targeting strategies for muscle tissue, covering serotype selection, promoter optimization, and delivery routes, and show how Cyagen's mouse models and preclinical CRO services help researchers translate these advances into reliable preclinical data.
Overcoming Delivery Barriers to De-risk Muscle Gene Therapy
Muscle is not a single target. Skeletal muscle makes up a large portion of body mass and exists in diverse fiber types with varying metabolic and regenerative properties. Smooth muscle lines blood vessels and internal organs, while cardiac muscle requires its own considerations for safe, long-term expression.
Diseases such as DMD affect skeletal and cardiac muscle, creating demand for vectors that can achieve broad yet controlled distribution. Systemic delivery is often essential, yet traditional AAV serotypes can show strong liver uptake or insufficient muscle penetration.
Figure 1: Basic structure of skeletal muscle [2]
Figure 2: Smooth muscle lineage development diagram [3]
The solution lies in the thoughtful combination of improved capsids, tissue-specific promoters, and optimized administration methods. These elements work together to maximize therapeutic benefit while minimizing off-target effects and safety risks.
Next-Generation AAV Serotypes for Enhanced Muscle Transduction
AAV9 systemic muscle delivery has long positioned standard AAV9 as a workhorse because of its ability to cross vascular barriers and transduce skeletal and cardiac muscle after intravenous administration. However, newer engineered variants are raising the bar.
Directed evolution approaches have yielded capsids with superior muscle tropism. One standout example is MyoAAV 2A, which demonstrates strong MyoAAV skeletal muscle tropism by achieving higher transgene expression in heart and multiple skeletal muscles compared with AAV9, while showing lower expression in the liver. This improved muscle-to-liver ratio is particularly valuable for reducing potential hepatic toxicity and increasing the therapeutic index [4].
Figure 3. MyoAAV 2A efficiently transduces mouse skeletal muscle following systemic administration [5]
While MyoAAV 2A represents a breakthrough for neuromuscular pipelines targeting skeletal and cardiac tissues, completely different therapeutic areas require alternative engineered capsids. For researchers focused on cardiovascular and pulmonary applications—where vascular or visceral smooth muscle is the primary target— variants such as AAV-PR have shown strong potential. These capsids can achieve efficient transduction of smooth muscle cells in the aorta and peripheral vessels following intravenous delivery, avoiding the off-target limitations of broader serotypes [5].
Figure 4. AAV-PR transduction of aortic smooth muscle cells and multiple peripheral tissues [5]
At Cyagen, we recognize that selecting or validating the right serotype is only half the battle. Our team routinely supports clients who need to test novel AAV constructs in disease-relevant backgrounds. We offer both catalog and custom-generated models that allow you to evaluate transduction efficiency, biodistribution, and functional outcomes in the exact genetic context of your target disease.
Muscle-Specific Promoters: The Key to Precision and Safety
Even the best capsid will underperform if the therapeutic gene is expressed in the wrong cells or at the wrong level. Tissue-specific AAV promoters muscle address this challenge directly by ensuring the therapeutic payload is expressed only where it is needed.
For skeletal muscle, modified versions of the muscle creatine kinase (MCK) promoter, particularly dMCK, tMCK, and MHCK7 (widely adopted), have become preferred choices [6-7]. The MHCK7 promoter drives robust expression across multiple muscle groups, including difficult-to-transduce muscles such as the diaphragm and soleus, making it highly effective for MHCK7 promoter AAV delivery [7]. Importantly, dMCK and tMCK maintain low activity in the liver, significantly improving the safety profile compared with ubiquitous promoters like CMV [6].
Figure 5. Activity and specificity of different promoters in muscle and liver tissues [6]
Figure 6. AP activity in cross-sections of the (a) diaphragm, (b) soleus muscle, (c) quadriceps muscle, and (d) gastrocnemius muscle [7]
For smooth muscle applications, the SM22α promoter (and enhanced versions incorporating additional regulatory elements) provides the necessary specificity while retaining sufficient strength for therapeutic benefit. Researchers have successfully used these promoters in cardiovascular gene therapy models to achieve targeted expression with reduced off-target effects [8].
Choosing the right promoter is not one-size-fits-all. Fiber-type preference, expression strength, and durability all matter. Cyagen’s scientific team can help you match promoter architecture to your specific research goals and then generate or select the mouse models best suited for testing that design.
Choosing the Right Delivery Route: Systemic vs. Local Administration
Administration method profoundly influences biodistribution and experimental outcomes.
Systemic intravenous delivery (commonly tail vein in rodent studies) is ideal when widespread muscle expression is required, such as in DMD gene therapy programs or when screening new capsid libraries for muscle tropism. It enables broad coverage but demands vectors with strong muscle specificity to avoid dose-limiting off-target organs.
Figure 7. Schematic illustration of tail vein injection [9]
Local intramuscular injection offers high efficiency for focused studies, whether investigating single-muscle function, testing localized therapies for injury or atrophy, or evaluating constructs in a specific muscle group before scaling to systemic approaches. Proper technique ensures consistent delivery and minimizes variability.
Figure 8. Basic structure of skeletal muscle [9]
Cyagen’s preclinical CRO services include both systemic and local AAV administration, along with downstream analyses such as vector genome quantification, transgene mRNA and protein expression, histological assessment of muscle pathology, and functional readouts (force generation, endurance, etc.). We design studies that align with your regulatory and publication goals.
In summary, the recommended injection methods, serotypes, and promoters for different target cells in muscle tissue are provided in Table 1 for reference only.
Table 1: Recommended Injection Methods and Doses
From Strategy to Data: How Cyagen Supports Muscle AAV Research
Educational content on targeting strategies is valuable, but execution requires the right biological systems. This is where Cyagen delivers clear advantages for academic and industry researchers alike. We maintain and continually expand a portfolio of muscle disease models, including multiple mdx variants suited for mdx mouse model preclinical testing and humanized DMD mouse models for AAV that cover clinically relevant exon regions. These models are especially powerful for testing muscle-targeted AAV therapies because they recapitulate key aspects of human disease pathology and allow evaluation of human-specific sequences or receptors.
Table 2: Selected Models for Muscle-Targeted AAV Therapy Testing
This table highlights selected models from Cyagen’s portfolio that are relevant to the described research directions. For programs exploring receptor-mediated delivery or enhanced targeting, we can generate custom models co-expressing relevant human receptors on muscle backgrounds. This capability helps bridge the gap between mouse studies and human translation.
Beyond model provision, our integrated gene therapy CRO platform supports the full workflow:
- Custom model generation (KO, KI, humanized, or tissue-specific)
- In vivo AAV vector testing and optimization
- Comprehensive biodistribution and expression profiling
- Efficacy studies with clinically relevant endpoints
- Safety and immunogenicity assessments
Cyagen provides the models, technical expertise, and data quality needed to move your program forward efficiently.
Ready to Advance Your Muscle Gene Therapy Program?
The strategies outlined above are already helping leading research teams achieve more efficient and safer muscle targeting. The next step is applying them in models that accurately reflect your disease of interest and therapeutic approach.
Cyagen is ready to partner with you. Whether you need a specific humanized model, custom gene editing for a novel target, or full-service AAV muscle gene therapy preclinical CRO support, including AAV vector biodistribution studies and functional efficacy studies, our team can design a solution tailored to your timeline and objectives.
Explore our current models and CRO capabilities at our website, or reach out directly to start the conversation. Together, we can turn promising AAV targeting strategies into meaningful therapeutic progress for patients with muscle disorders.
Reference
1. REGENXBIO Inc. REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 [press release]. May 14, 2026. Available from: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-positive-topline-results-pivotal-phase-iii
2. Gillies, A.R. and R.L. Lieber, Structure and function of the skeletal muscle extracellular matrix. Muscle Nerve, 2011. 44(3): p. 318-31.
3. Donadon, M. and M.M. Santoro, The origin and mechanisms of smooth muscle cell development in vertebrates. Development, 2021. 148(7).
4. Tabebordbar, M., et al., Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell, 2021. 184(19): p. 4919-4938.e22.
5. Ramirez, S.H., et al., An Engineered Adeno-Associated Virus Capsid Mediates Efficient Transduction of Pericytes and Smooth Muscle Cells of the Brain Vasculature. Hum Gene Ther, 2023. 34(15-16): p. 682-696.
6. Wang, B., et al., Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther, 2008. 15(22): p. 1489-99.
7. Salva, M.Z., et al., Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther, 2007. 15(2): p. 320-9.
8. Ribault, S., et al., Chimeric smooth muscle-specific enhancer/promoters: valuable tools for adenovirus-mediated cardiovascular gene therapy. Circ Res, 2001. 88(5): p. 468-75.
9. Gushchina, L.V., Intramuscular and Intravenous AAV-Mediated Gene Delivery in Mouse Models. Methods Mol Biol, 2026. 2975: p. 251-261.
